Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning

AI Summary

Amgen (AMGN) experienced a decline in its stock price following a warning from Kissei Pharmaceutical regarding liver risks associated with Tavneos. Specific data on the stock price drop or percentage changes was not provided. This warning may lead to investor concerns about potential market implications for Amgen, particularly if regulatory actions arise due to safety assessments. Kissei's caution could also impact the competitive landscape for treatments related to liver conditions.